Charles River Laboratories International, Inc. (NYSE:CRL) Receives Consensus Rating of “Moderate Buy” from Analysts

Charles River Laboratories International, Inc. (NYSE:CRL) has been given an average rating of “Moderate Buy” by the sixteen analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and twelve have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $220.75.

CRL has been the topic of several recent analyst reports. Morgan Stanley upped their price objective on shares of Charles River Laboratories International from $220.00 to $260.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. BNP Paribas Exane set a $250.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Robert W. Baird set a $213.00 price target on Charles River Laboratories International in a report on Friday, May 8th. Mizuho increased their price target on Charles River Laboratories International from $192.00 to $230.00 and gave the stock a “neutral” rating in a research note on Monday. Finally, Evercore reaffirmed an “outperform” rating and issued a $220.00 price objective on shares of Charles River Laboratories International in a research report on Friday, May 8th.

Charles River Laboratories International Trading Up 0.4%

Charles River Laboratories International stock opened at $229.08 on Friday. The stock has a market cap of $11.03 billion, a PE ratio of -60.93, a P/E/G ratio of 2.54 and a beta of 1.40. The stock has a 50-day moving average price of $191.82 and a 200 day moving average price of $186.50. Charles River Laboratories International has a 52 week low of $144.26 and a 52 week high of $237.86. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company had revenue of $995.83 million for the quarter, compared to analyst estimates of $977.46 million. During the same period in the prior year, the firm earned $2.34 EPS. The firm’s quarterly revenue was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Equities research analysts predict that Charles River Laboratories International will post 11.05 earnings per share for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, Director James C. Foster sold 75,000 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $225.00, for a total value of $16,875,000.00. Following the sale, the director directly owned 31,596 shares of the company’s stock, valued at approximately $7,109,100. This trade represents a 70.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of CRL. Tema Etfs LLC acquired a new stake in shares of Charles River Laboratories International in the fourth quarter worth approximately $26,000. Los Angeles Capital Management LLC acquired a new position in Charles River Laboratories International during the fourth quarter worth approximately $42,000. Sfam LLC purchased a new position in Charles River Laboratories International during the fourth quarter worth approximately $43,000. Activest Wealth Management raised its stake in Charles River Laboratories International by 10,900.0% during the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after purchasing an additional 218 shares during the period. Finally, Geneos Wealth Management Inc. grew its stake in shares of Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after buying an additional 145 shares during the period. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.